Roll-out of injectable PrEP in Zimbabwe will mean more young people are protected from HIV
Injectable PrEP is a promising HIV prevention method but advocates and health officials continue to grapple with the challenge of making it more widely available
Zimbabwe, with around 1.3 million HIV-positive individuals, including a significant 10% of young people under 19, faces a pressing challenge. Young women, in particular, are at a heightened risk – six times more vulnerable than young men, according to a 2022 UNICEF report. Various HIV prevention methods exist, including condoms, oral pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), and the dapivirine ring, which is inserted into the vagina and ensures safety for 28 days. However, oral PrEP requires taking a daily pill. Missing doses significantly heightens the risk of HIV infection. Daily adherence can be challenging, hence many sexually active young people have expressed enthusiasm for a novel solution: the PrEP injectable.
Zambia recently became the second country globally, following the USA, to introduce the long-acting HIV PrEP injectable outside of clinical trials. Dr. Nyaradzo Mgodhi led clinical trials for the injectable in Zimbabwe as part of the HTPN 084 CAB LA PrEP trials, in which seven African countries participated. Despite the promising outcomes, affordability remains a significant hurdle. A study in South Africa found that to be accessible, the PrEP injectable should cost between US$9 to US$15.
You can read more about the news here